Shilpa Medicare launches Sunitinib Capsules

15 Feb 2021 Evaluate

Shilpa Medicare has launched Sunitinib Capsules, under the brand name ‘SUNISHIL’. Three strengths of Sunitinib capsules 12. 5 mg, 25 mg and 50 mg is launched at an attractive price for the benefit of patients. Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities.

Sunitinib Capsules are indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Well-differentiated Pancreatic Neuroendocrine Tumors with Disease Progression in Adults.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

321.20 5.35 (1.69%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×